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Abstract
Background—Rb1 is a ginsenoside steroid glycoside found exclusively in the plant Panax 
ginseng. In an earlier report, we showed that Rb1 increased cell proliferation and reduced VEGF 
(vascular endothelial growth factor) secretion by human retinal pigment epithelial (ARPE19) cells.
Objective—In the present study, we hypothesized that chemical modification of Rb1 changes the 
level of VEGF secretion by ARPE19 cells.
Method—Three derivatives of Rb1 were chemically synthesized by hydrogenation (Rb1-H2), 
acetylation (Rb1-Acyl), and epoxidation (Rb1-Epoxy). Structural modifications were confirmed 
by 1H Nuclear Magnetic Resonance (NMR) spectra and Mass Spectrometry (MS). To test the 
biological activity, chemically modified compounds were added to cell culture media and 
incubated for 72 hours at a concentration of 250 nM at 37°C. Conditioned media were collected 
and cells were harvested/counted after treatment. Viable cell numbers were determined by the 
trypan blue dye exclusion method and VEGF levels by Enzyme-Linked Immunosorbent Assays 
(ELISA).
Results—Consistent with the prior report, results of the present study show Rb1 increased cell 
proliferation and decreased VEGF secretion. Similar to Rb1’s effect on cell proliferation, 
treatment with Rb1-H2, Rb1-Acyl and Rb1-Epoxy resulted in an increase in cell numbers. In 
contrast to Rb1-induced decrease in VEGF secretion, treatment with Rb1-H2, Rb-Acyl and Rb1-
Epoxy resulted in increased VEGF levels.
Conclusion—Chemical modifications of the ginsenoside Rb1 significantly affect the biological 
activity of VEGF secretion by ARPE19 cells. Additional SAR (Structure Activity Relationship) 
experiments will be conducted to study the detailed mechanisms by which how specific 
modifications of Rb1 functional groups alter biological activities.
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Ginsenosides or panaxosides are a class of steroid glycosides, and triterpene saponins, found 
exclusively in the plant genus Panax (ginseng). Although ginsenosides occur as a wide array 
of structurally related analogues, only a few of the major components have received 
attention due to trace occurrence and difficulty in isolation. Only major ginsenoside 
components have been the target of research, as they are viewed as the active compounds 
behind the claims of ginseng’s therapeutic efficacy. Individual ginsenosides appear to have 
distinct effects [1]. Whereas one particular ginsenoside stimulates the central nervous 
system, another sedates the central nervous system. Other ginsenosides produce different 
effects as balancing metabolic processes, decreasing blood sugar, improving muscle tone, 
stimulating the endocrine system and maintaining proper hormone levels. Research has 
shown that ginseng is effective in maintaining and even restoring cellular functions and 
therefore may reduce a number of symptoms of old-age [1]. Because ginsenosides appear to 
affect multiple pathways, their mechanisms of action are complex and yet to be fully 
elucidated.
Some ginsenosides have been isolated to purity by column chromatography. Based on 
structural differences, they are categorized into two main groups: the Rb1 group 
(characterized by the presence of protopanaxadiol: Rb1, Rb2, Rc and Rd) and the Rg1 group 
(characterized by the presence of protopanaxatriol: Rg1, Re, Rf, and Rg2) [2]. Recent 
studies have shown that acetyl modifications to the protopanaxadiol saponin compounds 
have notable activity against cancer cells [3]. In the present study, chemical modifications of 
Rb1 by hydrogenation (Rb1-H2), acylation (Rb1-Acyl), and epoxidation (Rb1-Epoxy) were 
performed and these Rb1 derivatives were tested (in ARPR-19 cells) to determine how their 
biological activities were changed in comparison to the parent Rb1 compound.
Macular degeneration is a progressive eye disease affecting as many as 15 million 
Americans and around 196 million globally. This disease attacks the macula of the eye, 
where our sharpest central vision occurs. Although it rarely results in complete blindness, it 
depletes the individual of all but the outermost, peripheral vision, leaving only dim images at 
the center of vision. AMD (Age-related Macular Degeneration) is characterized by 
angiogenesis, the abnormal growth of new blood vessels [4], which resulted in the leakage 
of fluid and blood into the retina, inducing scar formation and destroying central vision. 
AMD is a slow progressive disease associated with genetic as well as environmental risk 
factors including cigarette smoking, diet and prolong intense light exposure [5, 6].
Diabetic retinopathy is the result of retinal microvascular changes. Hyperglycemia-induced 
intramural pericyte apoptosis and thickening of the basement membrane [7]. These damages 
render retinal blood vessels more permeable. Pericyte death is associated with 
“hyperglycemia persistently activates protein kinase C-3 and p38 Mitogen-Activated Protein 
Kinase (MAPK), increasing the expression of PKC-3 signaling” [8, 9]. This signaling 
cascade leads to Platelet-Derived Growth Factor (PDGF) receptor-dephosphorylation and a 
reduction in downstream signaling from this receptor, resulting in pericyte apoptosis. An 
over accumulation of glucose and/or fructose damages blood capillaries in the retina with 
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fluid and lipids leakage to the macula, the region of the retina with high visual acuity. The 
fluid accumulation results in the swelling (or edema) of the macula, which blurs vision [10].
The retinal pigment epithelium (RPE) plays a critical role in the development and 
maintenance of adjacent photoreceptors in the vertebrate retina. The RPE and Bruch’s 
Membrane (BM) endure significant damage over one’s lifetime and such age-related 
changes are attributable to the development of AMD in certain individuals [11–13]. The 
RPE is also responsible for phagocytosis and degradation of shed-photoreceptors’ outer 
segments [14]. The disruption of this process may lead to retinal degradation, and the 
initiation or progression of AMD in humans [15]. The RPE secretes angiogenic (VEGF) and 
antiangiogenic (PEDF) cytokines, and therefore plays a key role in chorodial 
neovascularization, which can lead to AMD and possibly other eye diseases. [16–18].
Vascular endothelial growth factor (VEGF) is a cell signaling protein that stimulates 
vasculogenesis and angiogenesis. It is part of the negative feedback loop that restores the 
oxygen supply to tissues when blood is circulating. Serum concentration of VEGF is high in 
bronchial asthma and diabetes mellitus [12]. VEGF’s normal function is to create new blood 
vessels during embryonic development, new blood vessels after injury, muscle following 
exercise, and new vessels (collateral circulation) to bypass blocked vessels. Solid cancers 
cannot grow beyond a limited size without an adequate blood supply. However, cancers 
express VEGF to increase blood supply by neovascularlization. Overexpression of VEGF 
and other proteins cause vascular diseases such as diabetic retinopathy [12]. Drugs, such as 
bevacizumab, inhibit VEGF to control or halt disease development [4].
VEGF is member of the PDGF family of cysteine-knot growth factors. They are important 
signaling proteins involved in both vasculogenesis (the de novo formation of the embryonic 
circulatory system) and angiogenesis (the growth of blood vessels from pre-existing 
vasculature) [19]. In a previous study, we reported that Rb1 increases ARPE cell 
proliferation and inhibits VEGF release. In the present study, we observed that ARPE-19 
cells treated by chemically modified Rb1 also increased cell proliferation but they increase 
VEGF secretion. The molecular mechanism of such drug action is not known.
MATERIALS AND METHODS
Rb1
Rb1 was purchased from Fleton Natural Products (Chengdu, China) and was certified by 
Fleton to be chemically pure (99.8% pure by HPLC analysis) with the ability to be used as 
raw materials in food, drink, nutrition supplement and cosmetics field. The 1H NMR 
spectrum of commercial Rb1 was identical to that appearing in the literature [6]. Chemical 
modifications of Rb1 were carried out in the laboratory by standard organic reactions (Fig. 
1) and are described in the following paragraphs. Each of the compounds prepared in these 
studies was synthesized as previously reported, with modifications indicated below. The Pd 
catalyst for the hydrogenation was prepared as described by Felpin [20] and used without 
further purification. The m-CPBA oxidant was purified via liquid-liquid extraction using 
Et2O and NaHCO3 (aq) prior to use. Acetic anhydride and pyridine were purchased from 
Acros (Pittsburgh, PA) and used without purification. All reaction conditions were 
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performed in the absence of light. All other solvents and reagents were used without 
purification as obtained from the supplier.
Rb1-H2
To a stirred solution of Rb1 (17.9 mg, 16.1 μmol) in MeOH (1.0 mL) was added 6 wt% of 
Pd(OAc)2:10% Pd/C catalyst mixture (5:95) [20] in a reaction flask. Residue on glassware 
was rinsed with MeOH (0.5 mL) and transferred to the reaction flask. The flask was filled 
with N2 and placed on a Parr Shaker Hydrogenation Apparatus under H2 (30 psi) at room 
temperature for 16 hours. The mixture was filtered through a filter paper on sintered glass 
and the filtrate was evaporated under reduced pressure. The product, which was obtained in 
quantitative yield, exhibited a 1H NMR spectrum identical to that of the known Rb1-H2 [21], 
including the expected diagnostic loss of the triplet at δ 5.1 for the tri-substituted olefin 
proton of Rb1 (Fig. 2A and B). The LCMS trace exhibited one major peak that was shown to 
have expected m/z for Rb1-H2: MS (m/z) calcd for C54H93O23− [M-H] − 1109.6, found 
1109.6.
Rb1-Acyl
Acetic anhydride (0.60 μL, 6.76 μmol) was added to a reaction flask charged with Rb1 (5 
mg) in pyridine (1.50 μL, 18.03 μmol) and the reaction was stirred at room temperature 
overnight. The mixture was evaporated under vacuum (0.5 mm Hg) and residual pyridine, 
acetic anhydride, and acetic acid were removed by co-evaporation with MeOH (3 × 1 mL) 
under reduced pressure to yield a colorless oil in 96% yield. The 1H NMR spectrum of the 
product (Rb1-Acyl) exhibited signals consistent with the formation of the desired product 
[22] including the olefin triplet at δ 5.1 ppm, multiple singlets in the 2.0–2.2 ppm range 
expected for the 7 acetyl methyl groups, and downfield shifted signals δ 3–4 ppm expected 
for the C-Hs with the acetoxy groups (Fig. 2A and C). The LCMS trace exhibited one major 
peak that was shown to be comprised of molecules with the expected m/z: MS (m/z) calcd 
for C84H123O38+ [M+H]+ 1739.8, found 1739.8.
Rb1-Epoxide
To a stirred solution of Rb1 (11.2 mg, 10.1 μmol) in MeOH (2 mL) was added m-CPBA (2.8 
mg, 16.2 μmol) [23] and the reaction was stirred at room temperature overnight. The 
reaction was concentrated in vacuo and the oil was chromatographed (reversed-phase 
column chromatography using a C18 Sep-Pak and gradient elution from water to MeOH). 
Evaporation and solvent removal by lyophilization gave Rb1-Epoxide in 24% yield. The 
product exhibited a 1H NMR spectrum consistent with that of the data provided for known 
Rb1-Epox [24], however we present the 1H NMR in d-MeOH for easier interpretation. The 
spectrum included the loss of the diagnostic triplet at δ 5.1 for the tri-substituted olefin 
substrate of the reaction (Fig. 2A and D). The LCMS trace exhibited one major peak that 
was shown to have expected m/z of Rb1-Epoxy: MS (m/z) calcd for C54H91O24− [M-
H] − 1123.6, found 1123.6.
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Adult retinal pigment epithelial cells (ARPE19) were obtained from the American Type 
Culture Center (ATCC) and grown to confluence in T75 flasks in Dulbecco’s Modified 
Eagle Medium (DMEM)-F12 containing 5.5 mM glucose and 10% FBS at 37°C and 5% 
CO2. Cell were seeded into 24-well plates at a density of 20,000 cells per well and incubated 
for 24 hours at 37°C before treatments.
Introduction of Rb1 and Rb1 Modified Compounds to ARPE-19 Cells in Culture
Compounds (Rb1, Rb1-H2, Rb1-Acyl, Rb1-Epoxy) were diluted into serum free medium 
(DMEM: F12) to a final concentration of 250 nM. Each cell sample received a total of 250 
nM of its respective treatment/compound and were incubated for 72 hrs at 37°C and 5% 
CO2. DMSO (vehicle for Rb1) and appropriate vehicles for Rb1 modified compounds were 
used as controls.
Cell Viability and Cytokine Determination
Cell viability was determined by the trypan-blue dye exclusion method (Cat No. 
MT25900Cl; Corning via Fisher Scientific) and counting with a Neubauer hemacytometer. 
VEGF cytokine concentration in conditioned media was determined by Enzyme-Linked 
Immunosorbent Assay (ELISA) (Cat No. DVE00, R&D Systems, USA). Quantification of 
samples was determined by comparison to VEGF standard calibration curve (supplied with 
kit and performed per manufacturer’s instructions).
RESULTS
Chemical Modification of Rb1 by Hydrogenation, Acylation and Epoxidation
The hydrogenation and epoxidation transformations convert the double bond in native Rb1 
ginsenoside (Fig. 1) to the corresponding saturated chain and epoxide, respectively. The 
hydrogenation of Rb1 ginsenoside was confirmed upon observing the loss of the alkene 
proton of the substrate at 5.1 ppm. The Rb1-H2 1H NMR spectrum exhibited all other 
signals expected for the product (Fig. 2A and B). In contrast, the peracetylation converts all 
of the hydroxyl groups to acetoxy groups, diminishing aqueous solubility. The presence of 
the acetoxy group was confirmed by the appearance and appropriate integration of singlets 
near 2.0 ppm (Fig. 2C). In the epoxidation reaction, the alkene proton of Rb1 ginsenoside 
disappeared but other signals appeared as expected (Fig 2D). Rb1-Epoxy is anticipated to 
exist as a mixture of diastereomers, though neither spectroscopy nor spectrometry provided 
evidence for these stereoisomers.
Morphology of ARPE19 Cells
Cells were grown to confluence at P9 in T75 flasks (Fig. 3A). Cell seeded into 1 ml well and 
incubated for 24 hr exhibit morphology consistent with pre-confluent ARPE 19 cells (Fig. 
3B). Cell treated with Rb1 and Rb1 derivatives exhibited similar morphology suggesting that 
these compound did not induce major upregulation of protein expression and cell 
differentiation.
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Increase in Viable Cells After 72h Treatment with Rb1 and Rb1-Modified Compounds 
(Concentration = 250nM)
After treatment for 72 hrs, there was an increase of 33,000 cells between vehicle and Rb1 
groups (Fig. 4). Likewise, there were also increases in viable cell numbers between vehicle 
controls vs. treatments by Rb1 modified compounds: increase by 18,000 cells with Rb1-H2 
treatment, 6,000 cells with Rb1-Acyl treatment and 22,000 cells with Rb1-Epoxy (n = 3 for 
all data points; ±SEM, see Fig. 3). One-way analysis of variance shows a significant 
treatment effects (F=50; r 30.001).
Decrease in VEGF Release by Rb1 Treatment and Increase VEGF Release by Rb1-H2, Rb1-
Acyl and Rb1-Epoxy After 72hrs with 250nM
After 72 hrs of treatment, VEGF secretion from cells treated with Rb1 decreased from 0.05 
pg/cell (without Rb1) to 0.02 pg/cell (with 250 nM Rb1; Fig. 5). Meanwhile, treatment by 
Rb1-H2 resulted in an increase of VEGF to 0.21 pg/cell (Fig. 5). Treatment with Rb1-Acyl 
resulted in the highest level of increase VEGF (to 0.33 pg/cell) while treatment with Rb1-
Epoxy resulted in a much lower level of VEGF increase (to 0.05 pg/ml). Vehicle added to 
the conditioned media did not induce any changes in VEGF from control (0mM Rb1). (n = 3 
for all data points; ±SEM). One-way analysis of variance shows a significant treatment 
effects (F=30; r 30.001).
DISCUSSION
Previous reports have shown that Rb1 possesses potent anti-angiogenic activity in both in-
vivo and in-vitro studies [14, 3]. Results from the present study are consistent with those 
from our previous report that Rb1 induces ARPE-19 cell proliferation and inhibits VEGF 
secretion [14]. However, it is not known if chemical modifications of Rb1 could impact the 
efficacy of this cellular activity. Such a study on the structure versus function relationship 
(SAR) is important because Rb1 affects a significant change in VEGF (a known 
proangiogenic cytokine) secretion by RPE cells which are located near choroidal capillaries 
and other ocular vasculatures in the eye, and are a major producer of VEGF which 
contributes to the development of AMD and diabetic retinopathy.
Results from the present study strongly suggest that chemical modifications of Rb1 led to 
significant changes in its ability to induce cell proliferation and VEGF secretion. Chemically 
modified Rb1s produced upon hydrogenation, acylation and epoxidation all induce cell 
proliferation. In comparison to unmodified Rb1, epoxidation resulted in a slight increase in 
the efficacy of Rb1 to induce cell proliferation whereas hydrogenation resulted in a 
somewhat lower level of increase in cell proliferation (Fig. 4). In contrast, the addition of 
acyl group significantly reduced Rb1’s ability to induce an increase in cell proliferation. 
Although it is tempting to speculate that a change in hydrophobicity by the addition of the 
acetyl group and the epoxide may correlate to the decrease and increase in this cell 
(proliferation) activity, additional experiments are needed to substantiate this suggestion. 
Further experiments can be carried out to study if changes in Rb1 efficacy on cell 
proliferation are due to a change in its compatibility with hydrophobic cell membrane and/or 
intracellular signaling including gene activation [25, 26]
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Results from the present study also show that chemical modification of Rb1 significantly 
affects ARPE19 secretion of VEGF. Consistent with our prior report, the unmodified Rb1 
inhibited VEGF secretion (see Fig. 5) [5]. In contrast, chemical modification of Rb1 by 
hydrogenation, acylation and epoxidation resulted in an increase of VEGF release by 
ARPE19. The addition of acetyl groups resulted in the highest level of change – about 7-fold 
increase in VEGF release in comparison to control without Rb1. This is followed by 
hydrogenation, which induced a 4-fold increase and by epoxidation, with a 2-fold increase in 
VEGF release (compared to unmodified Rb1 which induced a 50% reduction in VEGF 
release; Fig. 5). It is not clear at this time how such structural changes render such large 
differences in this biological activity. Further experiments will be needed to investigate 
underlying mechanisms.
There are few pharmacokinetic and pharmacodynamic studies on the effects of Rb1 in 
humans, and therefore the toxic levels of ginsenosides are currently unknown [27]. Betts et 
al. [14] used concentrations of 0.25, 2.5, 25, and 250 nM Rb1 in an earlier experiment and 
observed a significant decrease in VEGF with an increase in cell proliferation, and therefore 
we chose to use 250 nM for all of our modified compounds in our experiment. Based on the 
information presented in several studies [16, 17], retinal angiogenesis is not a fully 
understood process in which retinal vascular endothelial cells proliferate and migrate 
through the damaged membrane. Based on the results of this and similar studies, Rb1 and its 
modified derivative Rb1H2 may be considered a viable homeopathic or pharmacological 
treatment for ocular disease like AMD and diabetic retinopathy which involves the process 
of choroidal neovascularization mediated by VEGF. This is the first study that compares the 
effects of Rb1 and a hydrogenated form of Rb1, as well as acylation and epoxidation. These 
modified compounds, compared to current therapy, could have a significant impact in the 
diabetic retinopathy and AMD markets.
CONCLUSION
Chemical modifications of ginsenoside Rb1 significantly change its biological activities in 
terms of cell viability and cytokine secretion by ARPE 19 cells. Additional experiments will 
provide results to illustrate mechanistic insight on how these structure changes lead to 
alternation of biological activities.
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Structure of Ginsenoside, Rb1 showing functional groups with chemical modification.
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NMR Spectra of Rb1 and chemically modified Rb1. A) Rb1 without chemical modification. 
B) Rb1-H2. C) Rb1-Acyl. D) Rb1-Epoxy. See “Result” section for a description on changes 
in 1H NMR signals corresponding to hydrogenation, acylation and epoxidation of Rb1.
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Photomicrographs of ARPE-19 cells in culture. A) confluent cells a Passage 9 after 5 days in 
culture in a P75 flask, 100× magnification B) Cells at Passage 10 were seeded in a 1 ml well 
at a seeding density of 20,000 cells per well and incubated for 24 hr in 37C, 5% CO, 200× 
magnification.
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Increase in cell proliferation after with Rb1 and Rb1-modified compounds. Data in this 
figure show the increase in viable cell number between vehicle control (0-Rb1) group and 
group of cell with Rb1 (or Rb1 modified compounds) treatment at 250 nM for 72 hr. (n = 3 
for all data points; ±SEM).
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hVEGF secretion by ARPE 19 cells is inhibited by Rb1 and enhanced by Rb1H2, Epoxide, 
or Rb1 Acylated Treatments. A) After 72 hrs, hVEGF secretion from cells treated with Rb1 
at 250 nM decreased to 382 pg/mL (compared to 600 pg/mL in vehicle control of 0-Rb1) 
whereas cells treated with Rb1-H2 at 250 nM increased to 659 pg/mL. Similarly, cell treated 
with Rb1-Acyl increased to 1157 pg/mL and Rb1-Epoxy, increased to 657 pg/mL. B) 
Compared to 0.05 pg/cell/mL in vehicle control of 0-Rb1, hVEGF decreased to 0.02 pg/cell 
in respond to Rb1. In contrast, Rb1-H2 treatment increased hVEGF secretion to 0.21 pg/
cell/mL, Rb1-H2, to 0.33 pg/cell by Rb1-Acyl, and to 0.09 pg/cell by Rb1-Epoxy treatment 
(n = 3 for all data points; ±SEM).
Betts-Obregon et al. Page 15
Curr Aging Sci. Author manuscript; available in PMC 2018 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
